ASCO 2024
ASCO 2024
Advertisement
Rob DillardHead and Neck Cancer | June 18, 2024
Primary care providers are highly involved in opioid prescribing for HNC survivors.
Read More
Rob DillardASCO 2024 | June 6, 2024
Some patients are unaware that metastatic breast cancer is incurable and that their treatment has no established end date.
Rob DillardASCO 2024 | June 6, 2024
Edmonton Symptom Assessment System completion rates need to be improved in patients with HNC.
Rob DillardASCO 2024 | June 4, 2024
One year of immunotherapy is optimal for treating patients with advanced melanoma.
Rob DillardASCO 2024 | June 4, 2024
Pembrolizumab use is increasing among patients with recurrent cervical cancer.
Rob DillardASCO 2024 | June 3, 2024
Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
Rob DillardASCO 2024 | June 3, 2024
Episodic future thinking may help breast cancer survivors lose weight.
Rob DillardASCO 2024 | May 31, 2024
Sexual health concerns are highly prevalent in women following breast cancer diagnosis.
Rob DillardASCO 2024 | May 30, 2024
Patients with head and neck cancer have increased rates of suicide compared with patients with other cancers.
Rob DillardASCO 2024 | May 30, 2024
An objective manual screening process may enhance diversity in gynecologic cancer clinical trial enrollment.
Rob DillardASCO 2024 | May 30, 2024
Medicaid expansion and improved access to health care services facilitate diagnosing melanoma at an early stage.
Advertisement
Advertisement
Advertisement
Latest News

July 12, 2024